Where Does an Eye Drop Go? Japan’s MRI Breakthrough Tracks Water Toward the Brain

A drop of water—and an unusually difficult question

A drop placed in the eye does not simply disappear. Water moves through intricate compartments of the eye and the tissues surrounding its connection to the brain. Scientists have long sought to understand those pathways, particularly as research explores how fluids and waste products circulate around the optic nerve and within the central nervous system.

On October 14, Japan’s National Institutes for Quantum Science and Technology (QST) and Hokkaido University announced a human MRI technique that detects where specially labeled water appears after it is applied as eye drops. Their images showed changes extending from the orbit toward the skull base and regions corresponding to the brain. The work is scheduled for presentation at the 54th Annual Meeting of the Japanese Society for Magnetic Resonance in Medicine on October 17. It should be described as an announced conference result, not an independently verified peer-reviewed paper.

How do you follow water when the body is already full of it?

Ordinary magnetic resonance imaging produces striking images by detecting signals associated mainly with hydrogen nuclei. Much of the signal comes from water already present in tissues. That makes MRI powerful for anatomy but limits its ability to distinguish a particular newly administered quantity of water from everything else.

The team instead used water enriched with oxygen-17, a stable isotope. Its unusual nuclear properties make it detectable with appropriate MRI equipment. Because oxygen-17 is not radioactive, the tracer does not impose exposure to ionizing radiation; that does not eliminate the usual medical considerations associated with specialized scans and administered tracers.

The instrument mattered as much as the eye drops

QST says researchers built a dedicated oxygen-17 radiofrequency coil and improved how signals were acquired. During MRI scanning, labeled H₂¹⁷O was repeatedly applied to the eyes. The technique identified changing oxygen-17 signals in and beyond the orbital region, including areas at the skull base and inside the cranium that overlap with the brain.

The finding is not a photograph of an open pipeline from the eye into the brain. A spatially changing tracer signal does not, on its own, identify every microscopic channel, prove a precise direction and speed for all fluid movement, or settle competing models of transport. What it supplies is a potentially valuable way to make those questions experimentally testable.

A partnership between imaging physicists and clinicians

The joint release credits QST’s Mari Miyata and Takayuki Obata, together with Hokkaido University professor Kohsuke Kudo and lecturer Hiroyuki Kameda, among the principal researchers. Their backgrounds bridge molecular imaging, specialized scanner development and clinical neuroradiology.

The initiative received support through Japan Agency for Medical Research and Development programs and used multinuclear MRI infrastructure. QST also acknowledges cooperation from Siemens Healthcare K.K. Those details help explain why a seemingly simple experimental idea required years of specialized technological development.

Why glaucoma researchers are interested

Glaucoma damages the optic nerve and can irreversibly narrow the field of vision. Elevated intraocular pressure is a major modifiable risk factor, yet in Japan many patients have so-called normal-tension glaucoma. Understanding the environment of the optic nerve may eventually help explain processes that pressure measurements alone cannot capture.

Fluid regulation within the eye, particularly the production and drainage of aqueous humor, should not be confused with a single confirmed eye-to-brain waste-disposal route. The new method is not validated as a glaucoma test and has not shown that monitoring labeled water improves diagnosis, predicts progression or prevents vision loss.

The scientific history of the brain’s plumbing

Researchers have spent decades debating how the brain moves water and clears metabolic waste. Since the early 2010s, the glymphatic hypothesis has drawn attention to movement along spaces associated with blood vessels and to the water-channel protein aquaporin-4, or AQP4. Studies have examined relationships with sleep, neurological disease and the exchange between cerebrospinal and interstitial fluids.

But there is no universally settled map of all neurofluid pathways in the living human brain. The institutions themselves note competing models and describe the broader field using the term “neurofluid.” A technique that measures a water tracer is especially intriguing in a research area where inferences have often depended on observing substances that are not water.

A research program years in the making

Hokkaido University’s diagnostic imaging group had been exploring oxygen-17-based water tracing well before the present announcement. In 2022, researchers reported a phase I randomized trial on the safety and feasibility of oxygen-17-labeled water for assessing cerebral water dynamics by indirect proton MRI. That earlier work did not establish the present eye-drop route; it helped demonstrate the larger research program’s technical and translational foundations.

Hokkaido’s published profiles of Professor Kudo describe efforts to improve temporal resolution and build practical approaches to analyzing fluid movement. The October 2026 result extends this line of investigation into an anatomically unusual question: what happens to tagged water after it enters through the eye?

From dementia to spaceflight: important possibilities, not proven applications

Brain-fluid dynamics have been investigated in relation to Alzheimer’s disease, traumatic brain injury, sleep and other conditions. Changes in body-fluid distribution are also a concern during long-duration spaceflight, when astronauts can develop ocular and vision abnormalities.

The new study does not establish the cause of dementia, identify a therapy for brain injury or explain astronauts’ visual changes. Each application would require studies that connect tracer measurements with disease mechanisms and clinically meaningful outcomes.

Could medication someday reach the brain through eye drops?

QST points to a possible long-term application: delivering therapeutics from the eye toward the brain with a relatively noninvasive method. It is an arresting prospect. If reliable, such a route might circumvent difficulties faced by some other forms of administration.

Yet water and drugs are not interchangeable. Drug molecules differ in size, binding, solubility, metabolism and toxicity. A tracer appearing near the brain says nothing definitive about whether a useful therapeutic dose can arrive at the right cellular target. No brain treatment delivered through this approach has been demonstrated by the October announcement.

What remains unknown

The public release does not provide all the information needed to appraise clinical performance: full participant characteristics, sample size, numerical tracer time courses, measurement uncertainty, detailed control conditions and independent replication. The October 17 conference presentation may clarify some of these points, and a subsequent peer-reviewed article would permit closer methodological review.

Researchers must also determine which anatomical pathways are responsible for the observed signal, how consistently the technique performs between people, and whether it distinguishes normal physiology from a specific disease state. With advances in imaging, the hardest question often comes after the picture appears: what exactly does the signal mean?

A window, not a verdict

The significance is methodological. Scientists have gained a new way to follow labeled water in regions that connect two complicated organ systems, opening a path toward better experiments in ophthalmology and neuroscience.

That should be exciting enough without announcing a cure for glaucoma or dementia. A technology capable of making an elusive process measurable can change the questions researchers are able to ask. The challenge now is to convert that measurement into reliable biology—and only then, perhaps, into medicine.